Loading
Palvella Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by JENKINS GEORGE M, was filed 01 Apr 2026.
Insider Decl.
159
Thresholds
n/a
Buy Volume
€1M
21 ops. · all time
Sell Volume
€33M
71 ops. · all time
Who traded when
BuySaleGeorge M. Jenkins5 buys26 sales
Kathleen Goin30 sales
Heron Elaine J1 buy
Kiritsy Christopher P1 sale
Since the insiders bought
- +12.0%Entry US$123.46 · Close at T+90 US$138.26
- -14.4%Entry US$131.51 · Close at T+90 US$112.59
- +342.2%Entry US$17.00 · Close at T+365 US$75.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Palvella Therapeutics, Inc. Strong Buy (bullish), based on 16 analysts. Average price target: US$231.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$123.92
Analyst consensus
16 analystsStrong buy
US$205.00Target US$231.25(+87%)US$267.00
Income statement
EBITDA-US$35.9M
Net income-US$41.7M0.0% margin
Valuation
PER (forward)-15.5x
P/Book8.2x
Balance sheet & cash
Market capUS$1.8B
Total debtUS$633k
Free Cash Flow-US$25M
Debt / Equity10%
Profitability & ownership
ROE-46.6%
ROA-22.1%
% insiders11.2%
% institutions103.8%
Last declaration on 23 October 2026
Declarations159 total
2,165 shares@ US$7.14Common StockSEC:0001104659-26-118466:0
2,148 shares@ US$9.08Common StockSEC:0001104659-26-118466:1
2,043 shares@ US$123.6214Common StockSEC:0001104659-26-118466:2
1,663 shares@ US$125.1645Common StockSEC:0001104659-26-118466:3
607 shares@ US$126.1949Common StockSEC:0001104659-26-118466:4
4,313 shares@ US$123.920.030% mcap7.0% of flowCommon StockSEC144:0001967940-26-000055
5,095 shares@ US$132.61650.036% mcap4.2% of flowCommon StockSEC:0001104659-26-115916:0
2,458 shares@ US$133.24830.018% mcap2.1% of flowCommon StockSEC:0001104659-26-115916:1
3,335 shares@ US$134.20860.024% mcap2.8% of flowCommon StockSEC:0001104659-26-115916:2
1,447 shares@ US$135.49680.011% mcap1.2% of flowCommon StockSEC:0001104659-26-115916:3
817 shares@ US$136.44440.0060% mcap0.7% of flowCommon StockSEC:0001104659-26-115916:4
2,004 shares@ US$128.52060.014% mcap1.6% of flowCommon StockSEC:0001104659-26-115916:5
1,644 shares@ US$129.23050.012% mcap1.3% of flowCommon StockSEC:0001104659-26-115916:6
990 shares@ US$130.48020.0070% mcap0.8% of flowCommon StockSEC:0001104659-26-115916:7
1,035 shares@ US$131.490.0074% mcap0.9% of flowCommon StockSEC:0001104659-26-115916:8
579 shares@ US$132.40460.0042% mcap0.5% of flowCommon StockSEC:0001104659-26-115916:9
922 shares@ US$133.72270.0067% mcap0.8% of flowCommon StockSEC:0001104659-26-115916:10
476 shares@ US$121.14030.0031% mcap0.4% of flowCommon StockSEC:0001104659-26-115916:11
2,072 shares@ US$122.61510.014% mcap1.6% of flowCommon StockSEC:0001104659-26-115916:12
2,604 shares@ US$123.28960.017% mcap2.0% of flowCommon StockSEC:0001104659-26-115916:13
920 shares@ US$124.36520.0062% mcap0.7% of flowCommon StockSEC:0001104659-26-115916:14
597 shares@ US$125.32710.0040% mcap0.5% of flowCommon StockSEC:0001104659-26-115916:15
505 shares@ US$126.55480.0035% mcap0.4% of flowCommon StockSEC:0001104659-26-115916:16
27,500 shares@ US$134.380.20% mcap30.0% of flowCommon StockSEC144:0001967940-26-000053
2,154 shares@ US$7.140.0009% mcap0.3% of flowCommon StockSEC:0001104659-26-108930:0
25 of 159 declarations
About Palvella Therapeutics, Inc.
At Palvella Therapeutics, Inc., a US healthcare company valued at USD 1.8 billion, 2026 holds 75 of the 153 filings in the record, which runs from June 15, 2016 to October 14, 2026. Sales weigh EUR 32.4 million across 68 trades (median EUR 125,471), against 21 purchases worth EUR 1.4 million (median EUR 40,931), so purchases are 24%.
The three largest sales come from holders of more than 10%: Orbimed Advisors LLC with EUR 10,318,078 on January 3, 2018 and EUR 5,201,422 on April 30, 2018, and Aquilo Capital Management, LLC with EUR 4,859,535 on July 21, 2020. The largest purchases are George M. Jenkins's (Director), EUR 423,620 on February 27, 2026, Elaine J. Heron's (Director), EUR 254,172 the same day, and Allan Reine's, EUR 183,069 on August 16, 2017.
Read moreShow less
George M. Jenkins has 31 filings, of which 5 purchases and 26 sales; Orbimed Advisors LLC 38, of which 8 sales. The record holds 51 option exercises and 13 filings of another kind. The last twelve months hold 82 filings, with 3 purchases and 54 sales. They come out a median of 2 days after the trade, and the 17 filers hold 11.2% of the capital. For 21 purchases, the stored 90-day result has a median of --6%, with 33% positive outcomes (stored past results, not a forecast).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
